Interview with Derek Williams, Vice President and General Manager, Vifor Pharma…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Address: Flughofstrasse 61, CH-8152 Glattbrugg,Germany
Tel: +41 58 851 80 00
Web: http://www.viforpharma.com/en/
Vifor Pharma is a fully integrated specialty pharma company within the Galenica Group. It unites all companies in the Pharma business sector of Galenica under one single umbrella organisation that researches, develops, produces and markets specific pharmaceutical products throughout the world.It is based on two main pillars: the business units Rx (prescription products) and Consumer Healthcare (OTC products). The operational basis of Vifor Pharma are lean and agile organisational structures. Vifor Pharma enjoys an increasing global presence. While the manufacture of all products is located in Switzerland and in the UK, the commercialisation is taken over by a wide network of affiliates and distributors all over the world.The business unit Vifor Pharma Consumer Healthcare manufactures and markets non-prescription products (OTC products) developed within Vifor Pharma or produced or sold under licence. Vifor Pharma plays a leading role in the area of non-prescription medicines, both in Switzerland and in selected countries of export. The focus of Vifor Pharma Consumer Health is on the development of own structures in key markets in Europe and on the continual optimisation of the product range through own developments and through the acquisition of products, licences and companies.
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
See our Cookie Privacy Policy Here
